Related Experiment Videos
Flavone acetic acid: a nonlinear pharmacokinetic model
A Gouyette1, D J Kerr, S B Kaye
1Clinical Pharmacology Unit (UA147 CNRS and U140 INSERM), Institut Gustave-Roussy, Villejuif, France.
Cancer Chemotherapy and Pharmacology
|January 1, 1988
Summary
This study investigated flavone acetic acid pharmacokinetics in 31 patients. A nonlinear model accurately predicted the maximal tolerated dose (MTD) and optimal dosing intervals to prevent drug accumulation.
Area of Science:
- Pharmacology
- Clinical Pharmacology
- Pharmacokinetics
Background:
- Flavone acetic acid (FAA) is an investigational anticancer agent.
- Understanding its pharmacokinetic profile is crucial for safe and effective clinical use.
Purpose of the Study:
- To characterize the pharmacokinetics of flavone acetic acid (FAA) in cancer patients.
- To develop a pharmacokinetic model to predict the maximal tolerated dose (MTD) and guide dosing strategies.
Main Methods:
- Phase I clinical trial involving 31 patients receiving intravenous infusions of FAA.
- Pharmacokinetic parameters were determined using a nonlinear model incorporating Michaelis-Menten kinetics.
- Dose escalation from 0.5 to 6.4 g/m2 over infusion durations of 1, 1.5, 3, and 6 hours.
Main Results:
- The mean elimination half-life was 4.8 hours, and the mean volume of distribution of the central compartment was 7.61 L/m2.
- The developed pharmacokinetic model predicted an MTD of 11.1 g/m2, closely aligning with the observed clinical MTD of 10 g/m2.
- The model demonstrated applicability to different infusion schedules, suggesting a 72-hour interval at the MTD to prevent accumulation.
Conclusions:
- A nonlinear pharmacokinetic model effectively describes flavone acetic acid disposition in cancer patients.
- The model provides a valuable tool for predicting MTD and optimizing dosing regimens.
- Dosing every 72 hours at the MTD is recommended to avoid flavone acetic acid accumulation.